Results From the CELESTIAL Trial for Patients with Advanced HCC
Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses results of the CELESTIAL trial. The results were clinically and statistically significant, Abou-Alfa notes.
Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses results of the CELESTIAL trial. The results were clinically and statistically significant, Abou-Alfa notes.
This randomized phase III trial compared treatment with cabozantinib (Cabometyx) versus a placebo in patients with advanced hepatocellular carcinoma (HCC) who had received a prior sorafenib (Nexavar) treatment. Findings showed a median overall survival (OS) of 10.2 months in the cabozantinib arm versus 8 months in the placebo arm.
There was also a progression-free survival rate over 5 months versus 1.5 months and a response rate of 4% versus 0.4% in the cabozantinib versus placebo arms, respectively. Patients experienced grade 3 and 4 adverse events, but none were unexpected for this drug, says Abou-Alfa.
Durvalumab Plus Chemo Continues to Improve Survival in Biliary Tract Cancer
April 16th 2024Results from a 3-year follow-up of the TOPAZ-1 trial showed that treatment with durvalumab plus chemotherapy in advanced biliary tract cancer continued to improve overall survival vs chemotherapy alone.
Read More
KEYNOTE-859 Outcomes Influence NCCN Guidelines on Pembrolizumab in Upper GI Cancer
April 10th 2024During a Case-Based Roundtable® event, David Zhen, MD, discussed how treatment of upper gastrointestinal cancer with pembrolizumab and chemotherapy is impacted by PD-L1 composite positive score, in the second article of a 2-part series.
Read More
